• Consolidated revenue increased by 26%, totaling 40.9 bln RUB (45.7 bln including VAT)
• Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased threefold, totaling 19.8 bln RUB for 2021
• EBITDA margin has reached 48%

The Pharmasyntez Group of Companies comprises five pharmaceutical facilities, which produce over 250 drug products for the treatment of socially significant diseases and over 45 drug substances.

The Company has three R&D centers to develop medicines and APIs. The staff comprises over 3,700 employees.